Skip to main content
Erschienen in: Neurological Sciences 4/2011

01.08.2011 | Original Article

Effects of heating coagulation of middle meningeal artery on plasma CGRP level and c-fos expression in migraine rat triggered by nitroglycerin

verfasst von: Xiaofeng Zhu, Yuechen Han, Wenping Xiong, Wenwen Liu, Sumei Lu, Jianfeng Li, Haibo Wang, Zhaomin Fan

Erschienen in: Neurological Sciences | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Current theory or hypothesis relevant to migraine indicates that trigeminovascular system plays a pivotal role in the pathophysiology of migraine. Particularly, release of neuropeptide and induction of c-fos like immunoreactivity (c-fos LI) within trigeminal nucleus caudalis neurons are regarded as activation markers of trigeminovascular system. In the present study, we set up a rat model for migraine triggered by nitroglycerin (NTG) and coagulated the middle meningeal artery by heating. Using this model, we determined the plasma calcitonin gene-related peptide (CGRP) level as well as the expression of c-fos in trigeminal nucleus caudalis of rats. We found that NTG led to markedly increase in plasma CGRP level and c-fos expression in trigeminal nucleus caudalis compared with the isotonic saline-treated group (P < 0.05). More importantly, heat coagulation of middle meningeal artery could decrease plasma CGRP level and c-fos expression in trigeminal nucleus caudalis (P < 0.05). Heat coagulation of middle meningeal artery may ameliorate sufferings of rat induced by NTG and play an important role in restraining the release of CGRP as well as the activation of neurons in trigeminal nucleus caudalis in rats following NTG infusion.
Literatur
1.
Zurück zum Zitat Mehrotra S, Gupta S, Chan KY, Villalón CM, Centurión D, Saxena PR, MaassenVanDenBrink A (2008) Current and prospective pharmacological targets in relation to antimigraine action. Naunyn Schmiedebergs Arch Pharmaco l378:371–394CrossRef Mehrotra S, Gupta S, Chan KY, Villalón CM, Centurión D, Saxena PR, MaassenVanDenBrink A (2008) Current and prospective pharmacological targets in relation to antimigraine action. Naunyn Schmiedebergs Arch Pharmaco l378:371–394CrossRef
2.
Zurück zum Zitat Greco R, Tassorelli C, Cappelletti D, Sandrini G, Nappi G (2005) Activation of the transcription factor NF-kappaB in the nucleus trigeminalis caudalis in an animal model of migraine. Neurotoxicology 26:795–800PubMedCrossRef Greco R, Tassorelli C, Cappelletti D, Sandrini G, Nappi G (2005) Activation of the transcription factor NF-kappaB in the nucleus trigeminalis caudalis in an animal model of migraine. Neurotoxicology 26:795–800PubMedCrossRef
3.
Zurück zum Zitat Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Glioti G, Trequattrini A, Palumbo R (1995) Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 15:384–390PubMedCrossRef Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Glioti G, Trequattrini A, Palumbo R (1995) Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 15:384–390PubMedCrossRef
4.
Zurück zum Zitat Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104–1110PubMedCrossRef Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104–1110PubMedCrossRef
5.
Zurück zum Zitat Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, Lines CR, Rapoport AM (2008) Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70:1304–1312PubMedCrossRef Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, Lines CR, Rapoport AM (2008) Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70:1304–1312PubMedCrossRef
6.
Zurück zum Zitat Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, Koppen H, Winner PK (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene- related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372:2115–2125PubMedCrossRef Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, Koppen H, Winner PK (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene- related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372:2115–2125PubMedCrossRef
7.
Zurück zum Zitat Lassen L, Haderslev P, Jacobsen V, Iversen H, Sperling B, Olesen J (2002) CGRP may play a causative role in migraine. Cephalalgia 22:54–61PubMedCrossRef Lassen L, Haderslev P, Jacobsen V, Iversen H, Sperling B, Olesen J (2002) CGRP may play a causative role in migraine. Cephalalgia 22:54–61PubMedCrossRef
8.
Zurück zum Zitat Bergerot A, Holland PR, Akerman S, Bartsch T, Ahn AH, MaassenVanDenBrink A, Reuter U, Tassorelli C, Schoenen J, Mitsikostas DD, van den Maagdenberg AM, Goadsby PJ (2006) Animal models of migraine: looking at the component parts of a complex disorder. Eur J Neurosci 24:1517–1534PubMedCrossRef Bergerot A, Holland PR, Akerman S, Bartsch T, Ahn AH, MaassenVanDenBrink A, Reuter U, Tassorelli C, Schoenen J, Mitsikostas DD, van den Maagdenberg AM, Goadsby PJ (2006) Animal models of migraine: looking at the component parts of a complex disorder. Eur J Neurosci 24:1517–1534PubMedCrossRef
9.
Zurück zum Zitat Ter Horst GJ, Meijler WJ, Korf J, Kemper RH (2001) Trigeminal nociception-induced cerebral Fos expression in the conscious rat. Cephalalgia 21:963–975PubMedCrossRef Ter Horst GJ, Meijler WJ, Korf J, Kemper RH (2001) Trigeminal nociception-induced cerebral Fos expression in the conscious rat. Cephalalgia 21:963–975PubMedCrossRef
10.
Zurück zum Zitat Juhasz G, Zsombok T, Modos EA, Olajos S, Jakab B, Nemeth J, Szolcsanyi J, Vitrai J, Bagdy G (2003) NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 106:461–470PubMedCrossRef Juhasz G, Zsombok T, Modos EA, Olajos S, Jakab B, Nemeth J, Szolcsanyi J, Vitrai J, Bagdy G (2003) NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 106:461–470PubMedCrossRef
11.
Zurück zum Zitat Stepień A, Jagustyn P, Trafny EA, Widerkiewicz K (2003) Suppressing effect of the serotonin 5HT1B/D receptor agonist rizatriptan on calcitonin gene-related peptide (CGRP) concentration in migraine attacks. Neurol Neurochir Pol 37:1013–1023PubMed Stepień A, Jagustyn P, Trafny EA, Widerkiewicz K (2003) Suppressing effect of the serotonin 5HT1B/D receptor agonist rizatriptan on calcitonin gene-related peptide (CGRP) concentration in migraine attacks. Neurol Neurochir Pol 37:1013–1023PubMed
12.
Zurück zum Zitat Tassorelli C, Joseph SA (1995) Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat. Brain Res 682:167–181PubMedCrossRef Tassorelli C, Joseph SA (1995) Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat. Brain Res 682:167–181PubMedCrossRef
13.
Zurück zum Zitat Tassorelli C, Greco R, Morazzoni P, Riva A, Sandrini G, Nappi G (2005) Parthenolide is the component of tanacetum parthenium that inhibits nitroglycerin-induced Fos activation: studies in an animal model of migraine. Cephalalgia 25:612–621PubMedCrossRef Tassorelli C, Greco R, Morazzoni P, Riva A, Sandrini G, Nappi G (2005) Parthenolide is the component of tanacetum parthenium that inhibits nitroglycerin-induced Fos activation: studies in an animal model of migraine. Cephalalgia 25:612–621PubMedCrossRef
14.
Zurück zum Zitat Offenhauser N, Zinck T, Hoffmann J, Schiemann K, Schuh-Hofer S, Rohde W, Arnold G, Dirnagl U, Jansen-Olesen I, Reuter U (2005) CGRP release and c-fos expression within trigeminal nucleus caudalis of the rat following glyceryltrinitrate infusion. Cephalalgia 25:225–336PubMedCrossRef Offenhauser N, Zinck T, Hoffmann J, Schiemann K, Schuh-Hofer S, Rohde W, Arnold G, Dirnagl U, Jansen-Olesen I, Reuter U (2005) CGRP release and c-fos expression within trigeminal nucleus caudalis of the rat following glyceryltrinitrate infusion. Cephalalgia 25:225–336PubMedCrossRef
15.
16.
Zurück zum Zitat Tassorelli C, Greco R, Morocutti A, Costa A, Nappi G (2001) Nitric oxide-induced neuronal activation in the central nervous system as an animal model of migraine: mechanisms and mediators. Funct Neurol 16:69–76PubMed Tassorelli C, Greco R, Morocutti A, Costa A, Nappi G (2001) Nitric oxide-induced neuronal activation in the central nervous system as an animal model of migraine: mechanisms and mediators. Funct Neurol 16:69–76PubMed
17.
Zurück zum Zitat Ploug KB, Boni LJ, Baun M, Hay-Schmidt A, Olesen J, Jansen-Olesen I (2008) K (ATP) channel expression and pharmacological in vivo and in vitro studies of the K(ATP) channel blocker PNU-37883A in rat middle meningeal arteries. Br J Pharmacol 154:72–81PubMedCrossRef Ploug KB, Boni LJ, Baun M, Hay-Schmidt A, Olesen J, Jansen-Olesen I (2008) K (ATP) channel expression and pharmacological in vivo and in vitro studies of the K(ATP) channel blocker PNU-37883A in rat middle meningeal arteries. Br J Pharmacol 154:72–81PubMedCrossRef
18.
Zurück zum Zitat Strecker T, Dux M, Messlinger K (2002) Nitric oxide releases calcitonin-gene-related peptide from rat dura mater encephali promoting increases in meningeal blood flow. J Vasc Res 39:489–496PubMedCrossRef Strecker T, Dux M, Messlinger K (2002) Nitric oxide releases calcitonin-gene-related peptide from rat dura mater encephali promoting increases in meningeal blood flow. J Vasc Res 39:489–496PubMedCrossRef
19.
Zurück zum Zitat Knyihár-Csillik E, Toldi J, Mihály A, Krisztin-Péva B, Chadaide Z, Németh H, Fenyo R, Vécsei L (2007) Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model. J Neural Transm 114:417–421PubMedCrossRef Knyihár-Csillik E, Toldi J, Mihály A, Krisztin-Péva B, Chadaide Z, Németh H, Fenyo R, Vécsei L (2007) Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model. J Neural Transm 114:417–421PubMedCrossRef
20.
Zurück zum Zitat Knyihar-Csillik E, Mihaly A, Krisztin-Peva B, Robotka H, Szatmari I, Fulop F, Toldi J, Csillik B, Vecsei L (2008) The kynurenate analog SZR-72 prevents the nitroglycerol-induced increase of c-fos immunoreactivity in the rat caudal trigeminal nucleus: comparative studies of the effects of SZR-72 and kynurenic acid. Neurosci Res 61:429–432PubMedCrossRef Knyihar-Csillik E, Mihaly A, Krisztin-Peva B, Robotka H, Szatmari I, Fulop F, Toldi J, Csillik B, Vecsei L (2008) The kynurenate analog SZR-72 prevents the nitroglycerol-induced increase of c-fos immunoreactivity in the rat caudal trigeminal nucleus: comparative studies of the effects of SZR-72 and kynurenic acid. Neurosci Res 61:429–432PubMedCrossRef
21.
Zurück zum Zitat Martin RS, Martin GR (2001) Investigation intomigraine pathogenesis: time course for effects of m.CPP, BW723C86 or glyceryltrinitrate on appearance of Fos-like immunoreactivity in rat trigeminal nucleuscaudalis (TNC). Cephalalgia 21:46–52PubMedCrossRef Martin RS, Martin GR (2001) Investigation intomigraine pathogenesis: time course for effects of m.CPP, BW723C86 or glyceryltrinitrate on appearance of Fos-like immunoreactivity in rat trigeminal nucleuscaudalis (TNC). Cephalalgia 21:46–52PubMedCrossRef
22.
Zurück zum Zitat Pardutz A, Krizbai I, Multon S, Vecsei L, Schoenen J (2000) Systemic nitroglycerin increases nNOS levels in rat trigeminal nucleus caudalis. Neuroreport 11:3071–3075PubMedCrossRef Pardutz A, Krizbai I, Multon S, Vecsei L, Schoenen J (2000) Systemic nitroglycerin increases nNOS levels in rat trigeminal nucleus caudalis. Neuroreport 11:3071–3075PubMedCrossRef
23.
Zurück zum Zitat Lambert GA, Donaldson C, Boers PM, Zagami AS (2000) Activation of trigeminovascular neurons by glyceryl trinitrate. Brain Res 887:203–210PubMedCrossRef Lambert GA, Donaldson C, Boers PM, Zagami AS (2000) Activation of trigeminovascular neurons by glyceryl trinitrate. Brain Res 887:203–210PubMedCrossRef
Metadaten
Titel
Effects of heating coagulation of middle meningeal artery on plasma CGRP level and c-fos expression in migraine rat triggered by nitroglycerin
verfasst von
Xiaofeng Zhu
Yuechen Han
Wenping Xiong
Wenwen Liu
Sumei Lu
Jianfeng Li
Haibo Wang
Zhaomin Fan
Publikationsdatum
01.08.2011
Verlag
Springer Milan
Erschienen in
Neurological Sciences / Ausgabe 4/2011
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-011-0486-7

Weitere Artikel der Ausgabe 4/2011

Neurological Sciences 4/2011 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.